Endoscopic Therapy of Malignant Bile Duct Strictures
Primary Purpose
Obstruction of Biliary Tree, Biliary Tract Cancer, Biliary Tract Neoplasms
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Radiofrequency ablation catheter (Habib EndoHBP)
Sponsored by
About this trial
This is an interventional treatment trial for Obstruction of Biliary Tree focused on measuring Bile duct, Cholangiocarcinoma, Bile duct stenosis, Malignant bile duct obstruction, Malignant bile duct stricture, Radiofrequency ablation, RFA, Endoscopic RFA catheter, EndoHPB
Eligibility Criteria
Inclusion Criteria:
- Documented malignant biliary obstruction requiring ERCP guided stenting
Exclusion Criteria:
- Coagulopathy (INR > 2.0 or PTT > 100 sec or platelet count < 50,000)
- Evidence of high-grade symptomatic duodenal obstruction
- Poor performance status
- Active suppurative cholangitis
- Complex stenoses will not be eligible for the trial
- Patients without access to duodenum or ampulla are not candidates for ERCP and stenting
- Candidates for a Whipple resection
- Patients who do not speak English
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Treatment
Arm Description
Radiofrequency ablation catheter
Outcomes
Primary Outcome Measures
Safety: Number of Bile Leak After RFA Procedure
Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)
Secondary Outcome Measures
Feasibility: Ease of the Radiofrequency Ablation Catheter Placement
Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.
Effectiveness: Change From Baseline in Bile Duct Diameter.
Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure. This will be measure as percentage change in improvement of the stricture.
Full Information
NCT ID
NCT01543607
First Posted
February 15, 2012
Last Updated
March 13, 2017
Sponsor
Massachusetts General Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01543607
Brief Title
Endoscopic Therapy of Malignant Bile Duct Strictures
Official Title
Endoscopic Therapy of Malignant Bile Duct Strictures: A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
March 2017
Overall Recruitment Status
Terminated
Why Stopped
Lack of enrollment
Study Start Date
February 2012 (Actual)
Primary Completion Date
February 2014 (Actual)
Study Completion Date
February 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Patients with malignant bile duct stenosis have poor prognosis and most of the patients are not good candidate for surgery at the time of diagnosis. Placement of the stent is the palliative care for these patients. However over 50% of the stents get blocked within 6-8 months. Use of the radiofrequency ablation before the stent placement may improve stent patency. Heat will be applied to the bile duct in order to open the blockage and prevent the re-growth of tissue into the stent. The investigators are looking to see how safe and feasible RFA (Radiofrequency ablation) catheter is in patient with malignant bile duct stenosis.
Detailed Description
As part of medical care subjects will be undergoing an endoscopic procedure (ERCP) in order to evaluate and stent a bile duct blockage. During the ECRP and just prior to the stent placement subjects will undergo the placement of a radiofrequency ablation catheter into the bile duct blockage. Heat will be applied to the bile duct in order to open the blockage and prevent the re-growth of tissue into the stent; after the radiofrequency ablation, stent will be placed. Three days after the procedure subjects will receive a phone call from the research coordinator to check any adverse or unwanted effects of the treatment. The study procedure (radiofrequency ablation) takes place over 10 minutes during ERCP. The subjects will undergo routine follow up for their medical problems. No follow up visits are required as part of the study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstruction of Biliary Tree, Biliary Tract Cancer, Biliary Tract Neoplasms
Keywords
Bile duct, Cholangiocarcinoma, Bile duct stenosis, Malignant bile duct obstruction, Malignant bile duct stricture, Radiofrequency ablation, RFA, Endoscopic RFA catheter, EndoHPB
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment
Arm Type
Experimental
Arm Description
Radiofrequency ablation catheter
Intervention Type
Device
Intervention Name(s)
Radiofrequency ablation catheter (Habib EndoHBP)
Other Intervention Name(s)
Habib EndoHBP
Intervention Description
Catheter placement into bile duct
Primary Outcome Measure Information:
Title
Safety: Number of Bile Leak After RFA Procedure
Description
Determination of safety will be measured by the presence of a bile leak( bile leak will be defined by contrast cholangiography)
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Feasibility: Ease of the Radiofrequency Ablation Catheter Placement
Description
Determine the feasibility of radiofrequency ablation catheter placement across malignant strictures with using a subjective scale, 0 is being impossible to place the catheter and 10 is being very easy to place the catheter.
Time Frame
2 years
Title
Effectiveness: Change From Baseline in Bile Duct Diameter.
Description
Effectiveness will be determined by change in stricture diameter (increase or decrease) after RFA procedure. This will be measure as percentage change in improvement of the stricture.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Documented malignant biliary obstruction requiring ERCP guided stenting
Exclusion Criteria:
Coagulopathy (INR > 2.0 or PTT > 100 sec or platelet count < 50,000)
Evidence of high-grade symptomatic duodenal obstruction
Poor performance status
Active suppurative cholangitis
Complex stenoses will not be eligible for the trial
Patients without access to duodenum or ampulla are not candidates for ERCP and stenting
Candidates for a Whipple resection
Patients who do not speak English
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William R Brugge, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
12. IPD Sharing Statement
Links:
URL
http://crnet.mgh.harvard.edu/trials.aspx?tId=4702
Description
Study information
Learn more about this trial
Endoscopic Therapy of Malignant Bile Duct Strictures
We'll reach out to this number within 24 hrs